Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: Implications for pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 4, 2009, Pages 411-415

  Braun, F ^a   Schocklmann H ^a   Ziegler, E ^a   Kunzendorf, U ^a   Armstrong, V W ^b   Renders, L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID ACYL GLUCURONIDE; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70349440959     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.129     Document Type: Article

References (44)

1. Nishikawa, K., Terasaki, PI. Annual trends and triple therapy-1991-2000. Clin. Transpl. 247-269 (2001).
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 345, 1321-1325 (1995).
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 61, 1029-1037 (1996).
4. Samaniego, M., Becker, B.N. & Djamali, A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat. Clin. Pract. Nephrol. 2, 688-699 (2006).
5. Dean, P.G. et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77, 1555-1561 (2004).
6. Flechner, S.M. et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 76, 1729-1734 (2003).
7. Grim, S.A., Slover, C.M., Sankary, H., Oberholzer, J., Benedetti, E. & Clark, N.M. Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant. Proc. 38, 3520-3523 (2006).
8. Knight, R.J. et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin. Transplant. 21, 460-465 (2007).
9. Troppmann, C., Pierce, J.L., Gandhi, M.M., Gallay, B.J., McVicar, J.P. & Perez, R.V. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 76, 426-429 (2003).
10. Chapman, J.R., O'Connell, P.J. & Nankivell, B.J. Chronic renal allograft dysfunction. J. Am. Soc. Nephrol. 16, 3015-3026 (2005).
11. Shipkova, M. et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol. 126, 1075-1082 (1999). (Pubitemid 29123740)
12. Bullingham, R.E., Nicholls, A.J. & Kamm, B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34, 429-455 (1998).
13. Behrend, M. & Braun, F. Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs 65, 1037-1050 (2005).
14. Staatz, C.E. & Tett, S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 46, 13-58 (2007).
15. Cox, V.C. & Ensom, M.H. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther. Drug. Monit. 25, 137-157 (2003).
16. Mignat, C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf. 16, 267-278 (1997).
17. Shaw, L.M., Nawrocki, A., Korecka, M., Solari, S. & Kang, J. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther. Drug. Monit. 26, 347-351 (2004).
18. Naito, T. et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol. Pharm. Bull. 29, 275-280 (2006).
19. Picard, N., Prémaud, A., Rousseau, A., Le Meur, Y. & Marquet, P. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br. J. Clin. Pharmacol. 62, 477-484 (2006).
20. Pescovitz, M.D. et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br. J. Clin. Pharmacol. 64, 758-771 (2007).
21. Kuypers, D.R. et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug. Monit. 25, 609-622 (2003).
22. Kuypers, D.R., Claes, K., Evenepoel, P., Maes, B. & Vanrenterghem, Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Pharmacol. Ther. 75, 434-447 (2004).
23. van Gelder, T. et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug. Monit. 28, 145-154 (2006).
24. Srinivas, T.R., Kaplan, B. & Meier-Kriesche, H.U. Mycophenolate mofetil in solid-organ transplantation. Expert Opin. Pharmacother. 4, 2325-2345 (2003).
25. Kuypers, D.R. et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol. 43, 866-880 (2003).
26. van Gelder, T., Klupp, J., Barten, M.J., Christians, U. & Morris, R.E. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug. Monit. 23, 119-128 (2001).
27. Kobayashi, M., Saitoh, H., Kobayashi, M., Tadano, K., Takahashi, Y. & Hirano, T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats. J. Pharmacol. Exp. Ther. 309, 1029-1035 (2004).
28. Cattaneo, D. et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am. J. Transplant. 5, 2937-2944 (2005).
29. Undre, N.A. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol. Dial. Transplant. 18 Suppl 1, i12-i15 (2003).
30. Büchler, M. et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin. Pharmacol. Ther. 78, 34-42 (2005).
31. El Haggan, W. et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. Transplant. Proc. 37, 864-866 (2005).
32. Mino, Y. et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Ther. Drug. Monit. 30, 656-661 (2008).
33. Braun, F. et al. An ex vivo model to study the intestinal biotransformation of immunosuppressives. Transplant. Proc. 32, 2536 (2000).
34. Soars, M.G., Petullo, D.M., Eckstein, J.A., Kasper, S.C. & Wrighton, S.A. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos. 32, 140-148 (2004).
35. Takeda, S. et al. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 67, 665-672 (2005).
36. Takeda, S. et al. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol. Pharm. Bull. 28, 2026-2027 (2005).
37. Takeda, S. et al. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab. Dispos. 34, 1277-1282 (2006).
38. Fremont, J.J., Wang, R.W. & King, C.D. Coimmunoprecipitation of UDP-glucuronosyltransferase isoforms and cytochrome P450 3A4. Mol. Pharmacol. 67, 260-262 (2005).
39. Ishii, Y., Takeda, S., Yamada, H. & Oguri, K. Functional protein-protein interaction of drug metabolizing enzymes. Front. Biosci. 10, 887-895 (2005).
40. Naesens, M. et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin. Pharmacol. Ther. 80, 509-521 (2006).
41. Kuypers, D.R., Verleden, G., Naesens, M. & Vanrenterghem, Y. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin. Pharmacol. Ther. 78, 81-88 (2005).
42. Shipkova, M. et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin. Chem. 44, 1481-1488 (1998).
43. Shipkova, M., Schütz, E., Armstrong, V.W., Niedmann, P.D., Oellerich, M. & Wieland, E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin. Chem. 46, 365-372 (2000).
44. Renders, L. et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin. Pharmacol. Ther. 81, 228-234 (2007).